Breaking News Instant updates and real-time market news.

IMMP

Immutep

$4.42 /

-0.23 (-4.95%)

08:12
10/28/21
10/28
08:12
10/28/21
08:12

Immutep reports Q1 cash receipts from customers $56K vs. $10K in Q4

Immutep provides an update on the ongoing development of its product candidates, eftilagimod alpha and IMP761 for the quarter ended 30 September 2021. Efti Development Program for Cancer Immutep will report final Overall Survival data from its Phase IIb AIPAC clinical trial evaluating efti in metastatic breast cancer as a late breaker poster at the Society for Immunotherapy of Cancer Annual Meeting 2021 taking place in the US and virtually from 10-14 November. Immutep previously reported initial OS data from approximately 60% of events in December 2020 at the San Antonio Breast Cancer Symposium. The study reported a promising and improving trend in OS in the total population with a median survival benefit of +2.7 months from efti plus chemotherapy, compared to chemotherapy plus placebo. In addition, a statistically significant OS benefit was observed in the efti group in key pre-defined patient groups, including patients under 65 years of age and those with low starting monocyte count. Immutep is continuing the preparation and planning steps for its Phase III clinical trial evaluating efti in patients with metastatic breast cancer. In July 2021, Immutep completed all the necessary competent authority steps with the US Food and Drug Administration and has received institutional review board approval to commence its Phase IIb TACTI-003 trial in the US. Recruitment has also opened in the Ukraine and more sites and countries will be added in the coming months. This follows the receipt of Fast Track designation in 1st line recurrent or metastatic head and neck squamous cell carcinoma from the US FDA in April 2021. In addition, Immutep will be presenting the trial design for TACTI-003 via a poster at the SITC 2021 conference in November In September 2021, Immutep enrolled the last patient into Stage 2 of Part B of the Phase II TACTI-002 study, completing recruitment of 2nd line PD-1/PD-L1 refractory non-small cell lung cancer patients into the trial. Recruitment is continuing for the additional 74 1st line NSCLC patients for the expansion of Part A, with 70 patients already enrolled. Recruitment for the expansion of Part A of the study continues to be ahead of the expected recruitment rate. Immutep reported favourable interim Overall Response Rates together with encouraging duration and depth of response in 1st line NSCLC and 2nd line HNSCC at ASCO in June 2021. The Company will report data from Part C of TACTI-002 at the SITC 2021 conference in November. Additional data from this study trial are planned to be reported in the first half of calendar year 2022. INSIGHT is an investigator-initiated Phase I trial at the Institute of Clinical Cancer Research, Krankenhaus Nordwest investigating different combination treatments with efti and a different route of administration for efti. INSIGHT consists of 5 different arms from stratums A to E. In August 2021, the first patient was enrolled and safely dosed in INSIGHT-003, also referred to as stratum C of INSIGHT. Patient recruitment is ongoing with 4 out of a total of 20 patients with various solid tumours now participating in the trial. First interim results are expected to be reported in 2022. Results from INSIGHT-004 were presented at the ESMO Congress 2021 held 16-21 September. The results are in line with the previous poster presentation at ASCO 2021. INSIGHT-005, known as stratum E of INSIGHT, will involve 12 patients with solid tumours and will evaluate efti in combination with bintrafusp alfa. It will be conducted under Immutep's collaboration agreement with Merck KGaA, Darmstadt, Germany. Separately to Immutep's ongoing collaboration agreement with Merck KGaA, Merck KGaA and GlaxoSmithKline announced a mutual decision to terminate their agreement to co-develop bintrafusp alfa. Accordingly, Immutep and Merck KGaA are working closely to determine the next steps for the INSIGHT-005 study. The investigator-initiated EAT COVID study is continuing at the University Hospital Pilsen in the Czech Republic. Patient recruitment into the trial by the hospital has been slower than anticipated due to a significant decline in the number of infections and improving vaccination rates in the Czech Republic. The Company will provide an update on the trial in due course. During the quarter, Immutep continued GMP manufacturing preparations for IMP761 and is planning for toxicology studies and other pre-clinical evaluations of this promising candidate.

  • 10

    Nov

IMMP Immutep
$4.42 /

-0.23 (-4.95%)

08/03/21 Ladenburg
Ladenburg starts Immutep with Buy into 'value-driving' events
08/03/21 Ladenburg
Immutep initiated with a Buy at Ladenburg
07/16/21 Maxim
Immutep assumed with a Buy at Maxim
06/10/21 Alliance Global Partners
Immutep price target raised to $9 from $6 at Alliance Global Partners

TODAY'S FREE FLY STORIES

General news
Fed's Bostic played down risks from the new Omicron variant » 17:40
11/26/21
11/26
17:40
11/26/21
17:40
$ECON

Economic Data

/

+

Fed's Bostic played…

Fed's Bostic played down risks from the new Omicron variant and its impact on the economy in a Fox New interview. Though there could be some slowing in overall activity, he doubted it would be as much as with Delta. He noted there is a lot of momentum in the economy and added it is certainly possible the FOMC could hike rates twice in 2022, stressing the Fed is not going to let inflation get out of control. He remains "very open" to speeding up the pace of the slowing in asset purchases. He sees late Q1 or early Q2 as a possible timeframe for ending purchases. Bostic is a voter this year and was on the dovish side of the spectrum until the last few months as inflation remained elevated.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Treasury Market Summary » 17:30
11/26/21
11/26
17:30
11/26/21
17:30
$ECON

Economic Data

/

+

Treasury Market Summary:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Week of 11/24 Fed balance sheet reserve bank credit $24.8B  16:34
11/26/21
11/26
16:34
11/26/21
16:34
$ECON

Economic Data

/

+

 
ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Week of 11/24 Fed balance sheet total assets $6.8B  16:34
11/26/21
11/26
16:34
11/26/21
16:34
$ECON

Economic Data

/

+

 
ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Week of 11/24 Fed balance sheet level $8.682T  16:34
11/26/21
11/26
16:34
11/26/21
16:34
$ECON

Economic Data

/

+

 
ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Technical Analysis
NASDAQ market internals summary » 16:23
11/26/21
11/26
16:23
11/26/21
16:23
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 16:22
11/26/21
11/26
16:22
11/26/21
16:22
$NYE

NYSE Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 469 / Declining Issues: 2860 -- for a ratio of 0.2 to 1. Advancing Volume: 346,472,000 / Declining Volume: 3,140,522,000 -- for a ratio of 0.1 to 1. New 52-Week Highs: 21 / New 52-Week Lows: 210.

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 16:13
11/26/21
11/26
16:13
11/26/21
16:13
SNOW

Snowflake

$361.94 /

+6.655 (+1.87%)

, CRWD

Crowdstrike

$233.73 /

+2.93 (+1.27%)

, SPLK

Splunk

$125.25 /

+0.2 (+0.16%)

, VEEV

Veeva

$288.19 /

-2.64 (-0.91%)

Technology Analysts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VEEV Veeva
$288.19 /

-2.64 (-0.91%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

11/19/21
Fly Intel: Top five analyst downgrades
11/19/21 Rosenblatt
Snowflake downgraded to Neutral on valuation at Rosenblatt
11/19/21 Rosenblatt
Snowflake downgraded to Neutral from Buy at Rosenblatt
11/16/21 Credit Suisse
Snowflake initiated with an Outperform at Credit Suisse
CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

11/24/21 Deutsche Bank
Crowdstrike price target lowered to $300 from $320 at Deutsche Bank
11/18/21
Fly Intel: Top five analyst initiations
11/18/21 DA Davidson
Crowdstrike initiated with a Buy at DA Davidson
11/15/21
Fly Intel: Top five analyst initiations
SPLK Splunk
$125.25 /

+0.2 (+0.16%)

11/17/21 Argus
Argus 'surprised' by Splunk's 'abrupt' CEO dismissal
11/16/21 Mizuho
Splunk price target lowered to $165 from $175 at Mizuho
11/16/21 Credit Suisse
Splunk initiated with an Outperform at Credit Suisse
11/16/21 Deutsche Bank
Splunk price target lowered to $155 from $180 at Deutsche Bank
VEEV Veeva
$288.19 /

-2.64 (-0.91%)

10/01/21 Stifel
Veeva assumed with a Buy at Stifel
09/03/21 SVB Leerink
Veeva price target raised to $296 from $294 at SVB Leerink
09/02/21 UBS
Veeva price target raised to $320 from $270 at UBS
09/02/21 Baird
Veeva price target raised to $349 from $340 at Baird
VEEV Veeva
$288.19 /

-2.64 (-0.91%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

  • 16
    Mar
CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

VEEV Veeva
$288.19 /

-2.64 (-0.91%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 16:08
11/26/21
11/26
16:08
11/26/21
16:08
CRM

Salesforce

$283.00 /

-6.155 (-2.13%)

, ZS

Zscaler

$337.00 /

-5.25 (-1.53%)

Technology Analysts…

Technology Analysts provide a recap of salesforce.com and Zscaler reported earnings on an Analyst/Industry conference call to be held on December 1 at 8:30 am.

ShowHide Related Items >><<
ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

11/23/21 BofA
Salesforce price target raised to $360 from $330 at BofA
11/23/21 Jefferies
Salesforce price target raised to $360 from $325 at Jefferies
11/23/21 Citi
Salesforce price target raised to $308 from $280 at Citi
11/22/21 Atlantic Equities
Atlantic Equities assumes 'low-risk' Salesforce at Overweight
ZS Zscaler
$337.00 /

-5.25 (-1.53%)

11/24/21 Deutsche Bank
Zscaler price target raised to $400 from $325 at Deutsche Bank
11/16/21 Credit Suisse
Zscaler initiated with an Outperform at Credit Suisse
11/15/21 Mizuho
Zscaler price target raised to $385 from $320 at Mizuho
11/09/21 BTIG
Zscaler price target raised to $401 from $324 at BTIG
ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

Hot Stocks
Moderna testing existing and new variant-specific vaccine candidates for Omicron » 15:37
11/26/21
11/26
15:37
11/26/21
15:37
MRNA

Moderna

$331.10 /

+57.83 (+21.16%)

Moderna announced updates…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

12:35 Today Piper Sandler
Moderna has been preparing for emergence of new variants, says Piper Sandler
11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
11/12/21 Piper Sandler
Piper keeps $348 target on Moderna after solid tumor data
MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

Conference/Events
UBS biotechnology analysts to hold an analyst/industry conference call » 15:29
11/26/21
11/26
15:29
11/26/21
15:29

Biotech Analysts Merle…

Biotech Analysts Merle & Rajavelu provide perspectives on the upcoming Phase 3 Data readouts for ATTR-CM (Transthyretin Amyloid Cardiomyopathy) data readouts on an Analyst/Industry conference call to be held on November 30 at 10 am.

Technical Analysis
NASDAQ market internals summary » 15:23
11/26/21
11/26
15:23
11/26/21
15:23
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 15:22
11/26/21
11/26
15:22
11/26/21
15:22
$NYE

NYSE Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 469 / Declining Issues: 2860 -- for a ratio of 0.2 to 1. Advancing Volume: 344,464,000 / Declining Volume: 3,113,466,000 -- for a ratio of 0.1 to 1. New 52-Week Highs: 21 / New 52-Week Lows: 210.

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 15:20
11/26/21
11/26
15:20
11/26/21
15:20

Technology Analysts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
UBS restaurants analyst to hold analyst/industry conference call » 15:15
11/26/21
11/26
15:15
11/26/21
15:15

Restaurants Analyst…

Restaurants Analyst Geiger, along with a quick serve restaurant coffee franchisee, discuss the industry on an Analyst/Industry conference call to be held on November 29 at 11 am.

Conference/Events
UBS consumer goods analyst to hold analyst/industry conference call » 15:12
11/26/21
11/26
15:12
11/26/21
15:12

Consumer Goods Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Cowen pharma/biotech analysts to hold an analyst/industry conference call » 15:03
11/26/21
11/26
15:03
11/26/21
15:03

Pharmaceuticals Analyst…

Pharmaceuticals Analyst Scala and Biotech Analyst Rodriguez-Dumont discuss the current status and future opportunities for women's health on an Analyst/Industry conference call to be held on December 3 at 10 am.

Conference/Events
Cowen financial services analyst to hold analyst/industry conference call » 14:59
11/26/21
11/26
14:59
11/26/21
14:59

Head of Equity…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Cowen media & entertainment analyst to hold analyst/industry conference call » 14:54
11/26/21
11/26
14:54
11/26/21
14:54
DISCA

Discovery

$24.72 /

-0.47 (-1.87%)

Media & Entertainment…

Media & Entertainment Analyst Creutz and TMT Policy Analyst Gallant discusses the Discovery-Time Warner merger-spin including the fundamental value, regulatory risk and when-issued market on an Analyst/Industry conference call to be held on December 2 at 11 am.

ShowHide Related Items >><<
DISCA Discovery
$24.72 /

-0.47 (-1.87%)

DISCA Discovery
$24.72 /

-0.47 (-1.87%)

11/08/21 Macquarie
Macquarie upgrades Discovery to Outperform, raises target to $40
11/08/21 Macquarie
Discovery upgraded to Outperform from Neutral at Macquarie
11/01/21 Bernstein
Bernstein upgrades Discovery to Market Perform, lowers target to $26
11/01/21 Bernstein
Discovery upgraded to Market Perform from Underperform at Bernstein
DISCA Discovery
$24.72 /

-0.47 (-1.87%)

  • 14
    Apr
DISCA Discovery
$24.72 /

-0.47 (-1.87%)

DISCA Discovery
$24.72 /

-0.47 (-1.87%)

DISCA Discovery
$24.72 /

-0.47 (-1.87%)

Conference/Events
Cowen ESG & restaurant analysts hold analyst/industry conference call » 14:47
11/26/21
11/26
14:47
11/26/21
14:47

ESG Policy Analyst Miller…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
FX Action: USD-JPY » 14:40
11/26/21
11/26
14:40
11/26/21
14:40
$ECON

Economic Data

/

+

FX Action: USD-JPY…

FX Action: USD-JPY revealed its safe-haven credentials, falling to near three-week lows of 113.05 on the back of the new Covid variant, and the slide in Treasury yields. The pairing had topped at 115.34 overnight. With answers on the new variant likely to take a couple of weeks, the yen may remain in favor for now.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Conference/Events
Cowen surface transport/logistics analyst holds analyst/industry conference call » 14:26
11/26/21
11/26
14:26
11/26/21
14:26

Surface…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Technical Analysis
NASDAQ market internals summary » 14:23
11/26/21
11/26
14:23
11/26/21
14:23
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 919 / Declining Issues: 3632 -- for a ratio of 0.3 to 1. Advancing Volume: 996,010,000 / Declining Volume: 2,412,588,000 -- for a ratio of 0.4 to 1. New 52-Week Highs: 35 / New 52-Week Lows: 349.

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 14:22
11/26/21
11/26
14:22
11/26/21
14:22
$NYE

NYSE Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Conference/Events
Cowen retail/luxury goods analyst to hold analyst/industry conference call » 14:22
11/26/21
11/26
14:22
11/26/21
14:22

Retail & Luxury Goods…

Retail & Luxury Goods Analyst Chen, along with RetailNext, discuss Black Friday and Cyber Monday on an Analyst/Industry conference call to be held on November 29 at 11 am.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.